Immune Therapeutics, Inc.
IMUN · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | -0.05 | 0.01 |
| FCF Yield | -4.97% | -16.02% | -2.87% | -0.03% |
| EV / EBITDA | -34.71 | 2.11 | -8.99 | -3.44 |
| Quality | ||||
| ROIC | 104.77% | 15.13% | 7.02% | 47.94% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.16 | -0.06 | -0.12 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | -366.87% | -20.71% | -20,451.82% | 99.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.85 | 1.35 | -2.67 | -2.26 |
| Interest Coverage | -9.66 | -3.50 | -1.85 | -3.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |